Rocket Pharmaceuticals (RCKT) Common Equity (2014 - 2026)

Rocket Pharmaceuticals has disclosed Common Equity across 13 years of filings, most recently posting $238.0 million for Q1 2026.

• Common Equity for Q1 2026 came in at $238.0 million, down 42.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $238.0 million (down 42.24% YoY), and the FY2025 annual result was $277.2 million, down 40.16% from the prior year.
• Common Equity came in at $238.0 million for Q1 2026 at Rocket Pharmaceuticals, down from $277.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $541.1 million in Q3 2023 to a low of $238.0 million in Q1 2026.
• The 5-year median for Common Equity is $403.0 million (2023), against an average of $398.4 million.
• Across the five-year window, Common Equity jumped 47.31% in 2023 and plunged 42.24% in 2026, its largest moves.
• Rocket Pharmaceuticals' Common Equity stood at $489.7 million in 2022, then advanced by 0.59% to $492.6 million in 2023, then decreased by 5.96% to $463.2 million in 2024, then plunged by 40.16% to $277.2 million in 2025, then declined by 14.13% to $238.0 million in 2026.
• The last three Common Equity figures came in at $238.0 million (Q1 2026), $277.2 million (Q4 2025), and $313.7 million (Q3 2025), per Business Quant data.